Objectives: Lack of data on the pharmacokinetics of efavirenz in pregnant women at the 400 mg reduced dose currently prevents universal roll-out. Population pharmacokinetic modelling was used to explore pharmacokinetic endpoints at 200, 400 and 600 mg daily doses in pregnant women stratified by CYP2B6 metabolic status.
Introduction
The current WHO guidelines on the use of antiretroviral (ARV) drugs for treating and preventing HIV infection recommend lifelong ART in all adults living with HIV, including pregnant women, regardless of CD4 cell count or clinical stage of disease. 1 The benefits associated with universal lifelong ART for prevention of mother-to-child transmission (PMTCT) of HIV are believed to outweigh the risks. 2 Like the Option B and B! from which it developed, this approach is expected to further reduce the risk of mother-to-child transmission (MTCT), improve maternal health benefits and reduce the risk of HIV transmission to sexual partners. However, implementation of universal ART coverage, though urgent, will significantly increase the funding required for diagnosis, drugs and personnel. This has generated interest in strategies for reducing the cost of ARVs drugs, including optimization of the manufacturing process, innovative formulations and dose reduction. 3 For instance, reduced doses of indinavir/ritonavir (400/100 versus 800/100 mg twice daily) and atazanavir/ritonavir (200/100 versus 300/100 mg once daily) were shown to have the same efficacy and lower side effects compared with the standard doses. 4, 5 Reduced doses of efavirenz (200 and/or 400 mg) were similarly reported to result in sustained virological suppression and reduced side effects despite lower plasma concentrations compared with the standard 600 mg dose. 6, 7 The non-inferiority of the 400 mg daily reduced dose compared with the standard dose was confirmed in the ENCORE 1 study, 8 resulting in its adoption by the WHO as part of alternative first-line ART in the 2016 guideline. However, pregnant women, patients with HIV/TB coinfection and adolescents younger than 12 years old are still excluded from this recommendation because of lack of efficacy and safety data.
Pregnancy is known to alter the pharmacokinetics of many drugs, including certain ARV drugs. 10 In a recent pharmacokinetic study, we reported significant differences in the magnitude of pregnancy-induced changes in efavirenz pharmacokinetics among HIV-positive women stratified by an SNP (516G . T; rs3745274) in the efavirenz disposition gene CYP2B6. 11 Pregnancy was associated with an approximately 100% increase in efavirenz apparent clearance (CL/F) in women with the CYP2B6 516GG genotype compared with post-partum control, resulting in median (range) minimum plasma concentration (C min ) of 0.59lg/mL (0.43-0.92), compared with the recommended 1.0 lg/mL.
11
However, the 1.0 lg/mL target was determined in patients with older regimens almost two decades ago, 12 and its validity is dubious given the lack of evidence of therapeutic failure in patients with plasma concentrations below 1.0 lg/mL in a number of studies. 13, 14 More recently, the non-inferiority of the 400 mg dose of efavirenz compared with the usual 600 mg dose was demonstrated in the ENCORE 1 trial, 15 despite plasma concentrations below 1.0 lg/mL in some patients. 16 Consequently, reduction of efavirenz dose to 400 mg has been suggested as a way of saving cost while maintaining efficacy and reducing adverse events. 3 Although the 400 mg reduced dose of efavirenz has not been evaluated in pregnant women, the observation of significantly lower plasma concentrations in pregnant women with the CYP2B6 516GG compared with other genotypes 11, 17 suggests the need for a cautious evaluation of this dose before roll-out in this population. 18 An ongoing study (ClinicalTrials.gov ID: NCT02499874) will evaluate key pharmacokinetic parameters of the 400 mg reduced dose of efavirenz in a cohort of pregnant women on suppressive ART (n " 25; plasma HIV-1 RNA ,50 copies/mL). However, the study is not sufficiently powerful to explore differences between genotype groups and complementary approaches are therefore needed to guide prospective efficacy trials towards the adoption of the 400 mg reduced efavirenz dose during pregnancy.
In the present study, we used a population pharmacokinetic modelling approach to compare plasma exposure resulting from a universal roll-out of the 400 mg reduced dose of efavirenz and CYP2B6 genotype-guided dose reduction in pregnant women. The analysis is based on data from a previously published study, Clinicaltrials.gov ID: NCT02269462.

Methods
Clinical study population and design HIV-positive pregnant women were recruited from three hospitals in Benue State, Nigeria: Bishop Murray Medical Centre, Makurdi; St Monica's Hospital, Adikpo; and St Mary's Hospital, Okpoga. Details about the study protocol have been previously reported 11 and are available at Clinicaltrials.gov (ID: NCT02269462). In brief, the clinical study was conducted in two phases in HIV-positive pregnant women receiving efavirenz in combination with two NRTIs. Those taking other drugs or herbs with known or uncertain interaction with ARVs (e.g. anti-TB drugs) were excluded. The purpose of the preliminary phase was to identify SNPs associated with efavirenz concentrations during pregnancy. In the second phase, the SNP independently associated with efavirenz plasma concentrations with the highest predictive power (CYP2B6 516G . T; rs3745274) was used to stratify patients into groups and randomly selected patients from each group were invited to participate in the intensive pharmacokinetic phase.
Sample collection, SNP genotyping and efavirenz quantification
As previously reported, 11 samples were collected at a single timepoint after dose in the preliminary phase for DNA extraction and efavirenz quantification. Genotyping was conducted for CYP2B6 516G . T (rs3745274), CYP2B6 983T . C (rs28399499) and seven other SNPs using TaqMan V R assays (Life Technologies Ltd, Paisley, Renfrewshire, UK). The influence of the genotype was tested on efavirenz CL by dividing the patient's population into three subgroups based on the combined effect of CYP2B6 516G . T and 983T . C. Individuals with two or more variant alleles (516GT plus 983TC, 516TT plus 983TT or 516TT plus 983TC) were classified as 'slow' metabolizers, those with one variant allele (516GT plus 983TT or 516GG plus 983TC) were classified as 'intermediate' metabolizers and those with no variant allele (516GG plus 983TT) were classified as 'fast' metabolizers. The current data set had only wild-type and heterozygous individuals for the rare CYP2B6 983T . C. Intensive pharmacokinetic samples (seven per subject) were collected between 0.5 and 24 h after an observed evening dose of 600 mg of efavirenz. Efavirenz was quantified using a validated LC-MS method.
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Population pharmacokinetic-pharmacogenetic model development
The model was developed using NONMEM V R (ICON, version VII 2.0). The model-building strategy was as follows: one-and two-compartment models with first-or zero-order absorption without and with lag-time were fitted to the data using the first-order conditional method of estimation. Proportional, additional, and combined proportional and additional error models were evaluated to describe residual variability. Inter-occasion variability was also tested. The minimal objective function value (OFV; equal to #2 log likelihood) was used as a goodness-of-fit metric with a decrease of 3.84 corresponding to a statistically significant difference between models (P " 0.05, v 2 distribution, one degree of freedom). Residual plots were also examined. Exponential errors following a log-normal distribution were assumed for the description of inter-individual variability in pharmacokinetic parameters, as shown in Equation (1) :
where h i is the pharmacokinetic parameter of the ith individual, h 1 is the population parameter estimate and g i is the inter-individual variability with a mean of zero and variance x 2 . Once the appropriate structural model was established, the following covariates were explored: age, body weight, gestational age and SNPs. An allometric weight model was applied to standardize the pharmacokinetic parameters using a standard weight (WTstd) of 70 kg. An allometric weight model for clearance parameters is given by CLwt " (WT/WTstd) 0.75 and for volume parameters is given by Vwt " (WT/WTstd) 1 where CLwt and Vwt are the weight functions for clearance (CL) parameters and volume of distribution (V) parameters, respectively, and WT is the individual weight value. 20, 21 Continuous variables were modelled using a power model with normalized covariate:
where h xi is pharmacokinetic parameter x in the ith individual and h x is the population parameter estimate as previously. In Equation (2) (for continuous covariates) COV i is the value of the covariate for the ith individual, COV median is the median value in the population data set and h cov is the exponent describing the covariate effect. Graphical methods were used to explore the relationship of covariates with individual predicted pharmacokinetic parameters. Each covariate was introduced separately into the Olagunju et al.
model and only retained if inclusion in the model produced a statistically significant decrease in OFV of 3.84 (P 0.05). A backwards elimination step was then carried out once all relevant covariates were incorporated and covariates were retained if their removal from the model produced a significant increase in OFV (.6.63 points; P 0.01, v 2 distribution, one degree of freedom).
To perform a visual predictive check, 1000 data sets were simulated using the parameter estimates defined by the final model with the SIMULATION SUBPROBLEMS option of NONMEM V R . Data sets were simulated for efavirenz (600 mg daily standard dose). From the simulated data, 90% prediction intervals (P5-P95) were constructed and superimposed on observed data from the original data set. At least 90% of data points within the prediction interval (5% above and below) were considered an adequate model. In addition, in order to confirm the stability and robustness of the model, a bootstrap resampling was used. Bootstrapping was performed with the software package Perl-speaks-NONMEM. 22 The median values and 95% CIs for the parameter estimates were obtained from 200 bootstrap replicates of the original data set and compared with the original population parameters.
To investigate the different dosing regimen scenarios (400 and 200 mg daily), pharmacokinetic simulations were performed and 90% prediction intervals of the simulated efavirenz concentrations for each category were plotted. For these simulations, dose-linear pharmacokinetics was assumed as has previously been demonstrated across human doses of this drug. 23 
Results
Data set
The analysis was based on 252 plasma efavirenz concentrations from HIV-positive pregnant women receiving regimens containing 600 mg of efavirenz daily for !4 weeks. Of these, 77 were sparse pharmacokinetic samples from 77 women and 175 were intensive pharmacokinetic samples from 25 women stratified based on their genotypes. Genotyping was successful for all 77 subjects. Patients' demographics and genotype frequencies are shown in Table 1 . This cohort and the data set on which the present analysis is based have been described previously.
11 Concentration-time profiles for individual patients in the intensive pharmacokinetic phase are shown in Figure 1 ; C 12 was below 1.0 lg/mL in 20% (5/20) of patients and C min in 44% (11/25) . The median (range) efavirenz AUC 0-24 , C max , C 12 and C min were 42.6 lgÁh/mL (21.7-203), 3.5 lg/mL (1.3-14.4), 1.6 lg/mL (0.78-8.6) and 1.0 lg/mL (0.43-5.2), respectively.
Population pharmacokinetic analysis
Efavirenz pharmacokinetics was best described by a onecompartment model with first-order absorption and first-order elimination. A one-compartment model with zero-order absorption or a two-compartment model did not improve the fit. In the model, residual variability was best described by a proportional structure; the inclusion of an additive structure did not improve the model. Inter-individual random effects were described by an exponential model, which was supported for CL/F, apparent volume of distribution (V/F) and absorption constant (k a ). In the basic model the mean population estimates for CL/F, V/F and absorption constant were 12.7 L/h, 268 L and 0.58 h #1 , respectively; the inter-individual variabilities in CL/F, V/F and absorption rate expressed by the coefficient of variation (CV%) were 63.3, 23.5 and 88.2, respectively. The residual variability was 0.08.
A total of five covariates (age, body weight, gestational age, CYP2B6 516G . T and CYP2B6 983T . C) were analysed using a stepwise backward elimination. The final covariate model is detailed in Table 2 . Only the genetic covariates were statistically significant. The impact of CYP2B6 genotypes on CL/F was used to categorize the population into three subgroups based on combined effect of 516G . T and 983T . C ( Table 2 ). The inclusion of genotypes in the final model decreased the OFV by 57 (P , 0.001, degree of freedom " 5). A summary of the final population estimates is presented in Table 2 . The inclusion of the genotypes decreased the CL/F inter-individual variability by 22.2%. A 90% prediction interval was generated from 1000 simulations for 600 mg of efavirenz once daily, with the covariate values of those individuals used in the building process (Figure 2 ). Visual predictive checks for the final model showed that predicted and observed data were in adequate agreement.
Dose optimization simulations
To investigate the effect of genetics on efavirenz concentration at the end of the dosing interval (C trough ), we simulated pharmacokinetic data for efavirenz, stratified for CYP2B6 516G . T and 983T . C genotype. Simulated concentration-time courses at steady-state were generated for the 200, 600 and 400 mg daily doses. The simulations were carried out with a population of individuals classified as slow, intermediate and fast metabolizers (Figure 3 ). For the 400 mg once-daily reduced-dose simulations, mean (90% CI) C 12 was 2.24 lg/mL (0.89-4.18) in pregnant women classified as slow At the 400 mg reduced dose, approximately 45% of women were predicted to have C 12 below the questionable 1.0 lg/mL cutoff compared with 23% at the standard 600 mg reduced dose. About 10% were predicted to have C 12 below 0.47 lg/mL (recommendation based on data from the ENCORE 1 trial 24 ) at the 400 mg Figure S1 (available as Supplementary data at JAC Online).
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dose compared with only 3% at 600 mg, increasing to 42% when the dose was further reduced to 200 mg (Table 3) . Also, the proportion of patients with predicted C 12 above 4.0 lg/mL decreased from 13.5% at 600 mg to 4.6% at the 400 mg reduced dose. Slow metabolizers were the most at risk with both doses (Table 3 ).
Discussion
One of the key issues delaying the universal roll-out of the 400 mg reduced dose of efavirenz is the lack of data on its pharmacokinetics, efficacy and safety in pregnant women. 1, 18 The analysis presented here has provided an early insight into efavirenz exposure in the context of the 400 mg reduced dose in this population. Universal adoption of the 400 mg reduced dose was predicted to achieve mean (90% CI) C 12 of 0.87 lg/mL (0.34-1.64) and 0.78 lg/mL (0.30-1.47) in pregnant women classified as intermediate and fast metabolizers, respectively, compared with median (range) of 2.14 lg/mL (0.579-7.89) and 1.60 lg/mL (0.734-3.65) reported in nonpregnant adults. 24 This is below the 1.0 lg/mL threshold previously associated with virological suppression. 12 However, no association was found between pharmacokinetic parameters and achieving a viral load of ,200 copies/mL at 96 weeks in the ENCORE 1 trial. In a comprehensive analysis, the sensitivity/specificity of using C 12 of 1.0 lg/mL for achieving a plasma viral load ,200 copies/mL at 96 weeks was 97.1%/84.6%, with a likelihood ratio of 6. 24 Using a range of potential C 12 cut-offs between 0.47 and 0.76 lg/mL also provided adequate sensitivity/specificity of 90% (100%/92.3% to 98.9%/92.3%) with a likelihood ratio of 13. The lower limits of the predictive interval for fast and intermediate metabolizers in the present study fall outside this range. In fact, a comparison of the AUC 0-24 and C 12 values across doses and metabolizing groups between the ENCORE 1 trial (see supplementary data) and the present analysis indicates about 50% reduction in pregnant women. 24 However, about 10% of pregnant women (16%, 13% and 1.2% of fast, intermediate and slow metabolizers, respectively) were predicted to achieve plasma concentrations below 0.47 lg/mL at 400 mg, compared with 3% at the 600 mg dose (Table 3) . Interestingly, data from the ENCORE 1 trial showed no difference in time to virological suppression between patients in the 400 and 600 mg groups. Plasma HIV RNA was .200 copies/mL at week 24 PopPK of 400 mg of efavirenz in pregnancy JAC in about 10% (33/321) of patients in the 400 mg group and in 9.7% (30/309) in the 600 mg group, further reducing to 1.2% (4/321) and 2.9% (9/309), respectively, at week 36 with a mean difference of #0.02 log 10 copies/mL (95% CI #0.14 to 0.10; P " 0.74). 8 Therefore, the 0.47 lg/mL C 12 cut-off appears reasonable for women who start ART during pregnancy for a viral load of ,200 -copies/mL to be achieved at delivery. In fact, despite risks of C trough ,1.0 lg/mL in pregnant women with CYP2B6 fast metabolizer status who received the standard 600 mg in two separate studies, 11, 17 further analysis showed that median C 12 was 1.01 lg/mL (range: 0.78-1.26) in one study 11 and no increased risk of MTCT was observed in the other. 17 The risk of C 12 ,0.47 lg/mL predicted for 10% of pregnant women who received the 400 mg reduced dose raises concerns, especially when therapy is started late in pregnancy. Further research is required to validate these predictions, but a dose reduction below 400 mg is unlikely to provide adequate exposure in pregnant women. This is important because suboptimal virological suppression in HIV-positive pregnant women results in detectable viral load at delivery and increases the risk of MTCT. 25, 26 For instance, viral load .1000 copies/mL near delivery was associated with a 12-fold increased risk of MTCT in a European collaborative study. 27 In a large multicentre US cohort study, Katz et al. 28 reported detectable viral load at delivery in 13% of 671 women who initiated ART during pregnancy, increasing to 23.9% when started during the third trimester, and identified gestational age at ART initiation, poor medication adherence and treatment interruptions as factors increasing risk. Among South African women who started ART before pregnancy (n " 574), 13% reportedly had viral load .1000 copies/mL. 29 MTCT risks of 0.25%, 2.0% and 8.5% were recently reported among women with viral loads of ,50, 50-1000 and .1000 copies/mL, respectively, at delivery. 30 Therefore, lack of virological suppression at delivery appears to be a major contributor to residual MTCT in women receiving ART. While it is still difficult to establish a pharmacokinetic target for PMTCT, the importance of undetectable viral load at delivery for PMTCT has been demonstrated in these studies. This highlights the need for continued caution with universal roll-out of the 400 mg reduced dose of efavirenz in pregnant women.
Therefore, the present analysis indicates that a confirmation of adequate virological suppression in pregnant women classified as CYP2B6 fast and intermediate metabolizers will be required before universal implementation of the 400 mg reduced dose. Meanwhile, where genotyping capacity already exists, retention of the 600 mg dose could be considered for fast and intermediate metabolizers to achieve C 12 of 1.31 lg/mL (0.51-2.48) and 1.17 lg/mL (0.45-2.21), respectively, while the 400 mg dose will achieve C 12 of 2.24 lg/mL (0.89-4.18) in slow metabolizers during pregnancy. This approach will also reduce the proportion of patients (mainly slow metabolizers) at risk of early treatment discontinuation caused by CNS side effects due to plasma concentrations .4.0 lg/mL; 5.2% with genotype-guided dosing compared with 13.5% with the universal 600 mg dose and 4.5% with the universal 400 mg dose. [31] [32] [33] In addition, only 3.4% of simulated pregnant women had C 12 below 0.47 lg/mL with genotypeguided dosing, compared with 10% with the universal 400 mg dose. Despite the difference in percentage of patients predicted to remain above this efficacy threshold, any future decision about implementation of the 400 mg dose needs to consider that (i) not Table 3 . Olagunju et al.
all patients below this threshold will fail therapy and (ii) these simulations do not take into account the incidence of CNS toxicity for either dose. It should be noted that CNS toxicity is more common in patients receiving 600 mg, 24 and this may subsequently impact adherence and therefore efficacy. 34 Schackman et al. 35 recently conducted cost-effectiveness analysis comparing the 600 mg standard dose with universal dose reduction to 400 mg and genotype-guided dosing. Assuming equal efficacy, current standard dose increases lifetime cost by $18500 and genotype-guided dosing was found to be more cost effective. However, universal dose reduction to 400 mg was more cost effective than both strategies under the most plausible scenarios. These findings are consistent with the findings of an earlier observational study. 36 Similar cost-effectiveness analysis is now warranted to compare the current standard care with targeted genotype-guided dose reduction and universal dose reduction to 400 mg in pregnant women. Such analysis should incorporate likely changes in rates of virological suppression with universal dose reduction in fast and intermediate metabolizers, as well as potential changes in available treatment options for pregnant women. Also, information analysis to quantify the value of undertaking additional research to investigate the effectiveness of a genotype-guided dose reduction will help in prioritizing research efforts. 37 Limitations in the present study include lack of data on virological suppression, which precludes pharmacokinetic-pharmacodynamic analysis, the limited number of patients in the different subgroups following stratification and lack of information on patient adherence for the sparse pharmacokinetic data. Also, the absence of the CYP2B6 983CC genotype in the cohort means ultra-slow metabolizers are not represented. In addition, differences in MTCT risks between slow, intermediate and fast metabolizers could not be assessed because data on MTCT were not available from the original study. The narrow range of body weight (48-83 kg) should be taken into account in interpreting the absence of association with efavirenz plasma concentrations in this cohort compared with the previous report by Poeta et al. 
